Springer eBooks may be purchased by end-customers only and are sold without copy protection (DRM free). Instead, all eBooks include personalized watermarks. This means you can read the Springer eBooks across numerous devices such as Laptops, eReaders, and tablets.
You can pay for Springer eBooks with Visa, Mastercard, American Express or Paypal.
After the purchase you can directly download the eBook file or read it online in our Springer eBook Reader. Furthermore your eBook will be stored in your MySpringer account. So you can always re-download your eBooks.
The hybridoma technique for producing monoclonal antibodies developed by Drs. Kohler and Millstein in 1975 revolutionized the field of tumor immunology. It is now clear that there are antigens associated with or restricted to human neoplasms that have biologic significance. Monoclonal antibodies have already been demonstrated to have great immunodiagnostic value, and it is anticipated that they will become a component of our therapeutic armamentarium. Most investigators in the field, however, feel the true potential of monoclonal antibodies in cancer therapy remains to be determined. Clearly the most encouraging results have been witnessed in the treatment of hematologic malignancies. This volume of Cancer Treatment and Research explores the current state of the art of immunoconjugate therapy of hematologic malignancies. The first chapter, authored by Drs. Rosen and Kuzel, reviews the current status of radioimmunotherapy of lymphoma. Results of clinical investigations utilizing radiolabeled immunoconjugates in B-cell lymphomas, T-cell lym phomas, and Hodgkin's disease are discussed. In addition, obstacles to effective antibody therapy are highlighted and toxicities are summarized. Chapter 2, written by Drs. Sgouros and Scheinberg, critiques the treat ment of leukemia with radiolabeled monoclonal antibodies. In this chapter, the unique features of leukemia that make it particularly suitable for radio immunotherapy are discussed, an overview of selected clinical trials is presented, and a treatment planning approach to radioimmunotherapy in corporating biologic and physical parameters is reviewed.
1. Radioimmunotherapy of Lymphoma; T.M. Kuzel, S.T. Rosen. 2. High Dose Radioimmunotherapy of Lymphomas; O. Press, J. Eary, C. Badger, F. Applebaum, G. Wiseman, D. Matthews, P. Martin, I. Bernstein. 3. The Treatment of Leukemia with Radiolabeled Monoclonal Antibodies; G. Sgouros, D. Scheinberg. 4. New Approaches to Radiolabeling Monoclonal Antibodies; A.M. Zimmer, S. Spies. 5. Immunotoxin Therapy of Lymphoma; M. Grossbard, L. Nadler. 6. Immunotoxins for the Therapy of Graft vs Host Disease; D. Salzman, F. Lemaistre. 7. Recombinant Fusion Toxins - a New Class of Targeted Biologic Therapeutics; T. Woodworth, J. Nichols. 8. Chimeric Antibodies for the Treatment of Hematologic Malignancy; M. Dyer. 9. Immunoconjugate Therapy of Hematologic Malignancies; M. Fanger, P. Morganelli, P. Guyre. Index.